Author

Wojciech Cebula

THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)
THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)

Wojciech Cebula  et al.

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Wojciech Cebula  et al.

Item 1 - 2 / 2
1